Oncology/Autoimmune Diseases

Envafolimab, for example, is a novel single-domain PD-L1 antibody formulated for subcutaneous injection. It has been approved for use in certain types of advanced solid tumors and is administered within 30 seconds, significantly shortening treatment time and potentially reducing adverse reactions associated with intravenous infusion.